Viridian Therapeutics, Inc.\DE (VRDN)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NASDAQ
Market cap: $2.09B
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Latest financial period: June 30, 2026
Filed with the SEC: August 6, 2026
Estimated earnings date: November 4, 2026
Profit #1441 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 2.1% | 2.8% | 3.4% | 3.3% |
Growth #352 of 1484 companies
Payout #1117 of 1484 companies
Safety #925 of 1484 companies
Price #1469 of 1484 companies
